Anavex Life Sciences Corp (AVXL)

[crescentmotor]

They will be able to see that donepezil + blarcamesine, as well as blarcamesine alone, perform better than donepezil alone.

Great point. The only downside to including patients on SOC is if Blarcamesine underperforms on a comparative basis with regards to these SOC patients and such findings are the point of scientific research. The data can easily be sliced to include/exclude the patients on donepezil.